多发性骨髓瘤自体移植后免疫微环境重建模式与结局相关
该研究纳入58例接受 upfront 自体干细胞移植的多发性骨髓瘤患者,在移植后60至100天用 CyTOF 和 Luminex 评估细胞及体液免疫微环境。识别出两种细胞免疫微环境模式,其中Group 1富集终末分化(免疫衰老或耗竭)和初始T细胞,该组血液学反应更差、生存更差、血液学进展时间更短,且独立于已知风险因素。体液免疫微环境两组无差异,高危FISH状态及早期或晚期复发间细胞/体液免疫微环境也无差异;男性CD16阴性NK细胞水平更高。
要点
- 移植后60至100天T细胞免疫微环境失调(耗竭/衰老与初始T细胞富集)与更差血液学反应和生存相关。
- 该关联独立于已确立的风险因素,且体液免疫微环境两组无差异。
- 高危FISH状态及早期或晚期复发间细胞/体液免疫微环境未见差异。
核心结论
- 自体移植后T细胞免疫微环境功能障碍(部分如耗竭可能可逆)与更差结局相关。
研究设计与样本
- 研究纳入58例接受 upfront 自体干细胞移植的多发性骨髓瘤患者。
- 在移植后第60至100天用 CyTOF 评估细胞免疫微环境、用 Luminex 评估体液免疫微环境。
主要发现
- 识别出2种细胞免疫微环境模式,Group 1富集终末分化(免疫衰老或耗竭)和初始T细胞。
- Group 1移植后血液学反应更差、生存更差、血液学进展时间更短,且独立于已确立风险因素。
- 两组间体液免疫微环境无差异。
- 高危FISH状态及早期或晚期复发间细胞/体液免疫微环境无差异。
- 男性CD16阴性NK细胞水平更高,CD16是介导抗体依赖细胞毒作用的关键受体。
临床怎么用
- 移植后T细胞免疫微环境特征可能用于指导自体移植后维持/巩固治疗的合理选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The immediate postautologous stem cell transplant (ASCT) period in multiple myeloma represents a unique opportunity for long-term disease control because many patients have eradicated most of their disease but also a challenge because it is characterized by the increase of immune subsets detrimental to tumor immunosurveillance. The impact of the tumor immune microenvironment (iTME) in post-ASCT outcomes is not known. In this study, we included 58 patients undergoing upfront ASCT and evaluated their cellular and humoral iTME with cytometry by time of flight (CyTOF) and luminex, respectively, at day +60 to 100 post-ASCT. We identified 2 cellular iTME patterns. Group 1 was enriched in T-cell subsets at the opposite ends of the spectrum of T-cell differentiation compared with the rest of the patients, that is, cells already terminally differentiated (immune senescent or exhausted) and naive T cells. This group had worse hematologic responses post-ASCT, inferior survival, and shorter time to hematologic progression independent of established risk factors. No differences in the humoral iTME were noted between the 2 groups. In addition, no differences in the cellular/humoral iTME were noted according to high-risk fluorescence in situ hybridization status, early or late relapse. Finally, males had higher levels of natural killer cells negative for CD16, a key receptor mediating antibody-dependent cell cytotoxicity, a major mechanism of antitumor efficacy by therapeutic antibodies such as elotuzumab. Our findings suggest that T-cell iTME dysfunction post-ASCT, some of which could be reversible (exhaustion), correlates with worse outcomes. These results could be used to guide rational selection of post-ASCT maintenance/consolidation approaches in these patients.
引用
- Parmar H, Gertz M, Anderson EI, et al. Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma. Blood Adv. 2021. PMID: 33787859. doi:10.1182/bloodadvances.2020003857
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。